Fractyl Health Future Growth
Future criteria checks 2/6
Fractyl Health's earnings are forecast to decline at 57.3% per annum while its annual revenue is expected to grow at 161.3% per year. EPS is expected to decline by 13.4% per annum.
Key information
-57.3%
Earnings growth rate
-13.4%
EPS growth rate
| Medical Equipment earnings growth | 17.1% |
| Revenue growth rate | 161.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 12 | N/A | N/A | N/A | 1 |
| 12/31/2025 | N/A | -119 | N/A | N/A | 1 |
| 12/31/2024 | 0 | -56 | N/A | N/A | 1 |
| 9/30/2024 | 0 | -69 | -61 | -59 | N/A |
| 6/30/2024 | 0 | -66 | -54 | -52 | N/A |
| 3/31/2024 | 0 | -87 | N/A | N/A | N/A |
| 12/31/2023 | 0 | -94 | -43 | -43 | N/A |
| 9/30/2023 | 0 | -86 | -45 | -45 | N/A |
| 6/30/2023 | 0 | -81 | -44 | -43 | N/A |
| 3/31/2023 | 0 | -63 | N/A | N/A | N/A |
| 12/31/2022 | N/A | -64 | -46 | -46 | N/A |
| 9/30/2022 | N/A | -65 | -44 | -44 | N/A |
| 6/30/2022 | N/A | -63 | -43 | -43 | N/A |
| 3/31/2022 | N/A | -58 | -38 | -38 | N/A |
| 12/31/2021 | N/A | -53 | -34 | -33 | N/A |
| 9/30/2021 | N/A | -47 | -32 | -31 | N/A |
| 6/30/2021 | N/A | -44 | -31 | -31 | N/A |
| 3/31/2021 | N/A | -42 | -31 | -31 | N/A |
| 12/31/2020 | N/A | -41 | -31 | -31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GUTS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GUTS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GUTS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GUTS's revenue (161.3% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: GUTS's revenue (161.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GUTS's Return on Equity is forecast to be high in 3 years time